BC
AVDL

Broadfin Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Broadfin Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$7.77M Sell
1,029,012
-2,073,661
-67% -$11M 1.04% 28
2019
Q3 		$12.9M Hold
3,102,673
– – 2.39% 14
2019
Q2 		$8.97M Hold
3,102,673
– – 1.95% 18
2019
Q1 		$4.47M Hold
3,102,673
– – 0.92% 35
2018
Q4 		$8.01M Buy
3,102,673
+309,900
+11% +$1.05M 1.05% 29
2018
Q3 		$12.3M Buy
2,792,773
+68,110
+2% +$368K 1.8% 21
2018
Q2 		$16.7M Buy
2,724,663
+100,000
+4% +$702K 2.63% 13
2018
Q1 		$19.1M Buy
2,624,663
+32,942
+1% +$290K 2.98% 12
2017
Q4 		$21.3M Sell
2,591,721
-976,401
-27% -$9.16M 3.47% 13
2017
Q3 		$37.5M Sell
3,568,122
-565,342
-14% -$5.4M 5.54% 5
2017
Q2 		$45.6M Sell
4,133,464
-261,000
-6% -$2.62M 5.54% 5
2017
Q1 		$42.5M Hold
4,394,464
– – 5.15% 5
2016
Q4 		$45.7M Hold
4,394,464
– – 5.07% 5
2016
Q3 		$54.5M Hold
4,394,464
– – 4.88% 5
2016
Q2 		$47.2M Hold
4,394,464
– – 4.59% 6
2016
Q1 		$48.5M Hold
4,394,464
– – 4.69% 4
2015
Q4 		$53.7M Hold
4,394,464
– – 3.3% 9
2015
Q3 		$71.7M Sell
4,394,464
-580,720
-12% -$12.8M 3.99% 4
2015
Q2 		$105M Buy
4,975,184
+255,225
+5% +$4.58M 5.67% 3
2015
Q1 		$84.9M Sell
4,719,959
-433,231
-8% -$6.78M 6.61% 2
2014
Q4 		$88.3M Buy
5,153,190
+147,577
+3% +$2.11M 7.68% 2
2014
Q3 		$71.6M Sell
5,005,613
-262,298
-5% -$3.77M 7.51% 1
2014
Q2 		$79M Hold
5,267,911
– – 7.71% 1
2014
Q1 		$70.6M Buy
5,267,911
+1,500,000
+40% +$16.1M 6.84% 1
2013
Q4 		$30.3M Hold
3,767,911
– – 4% 7
2013
Q3 		$24.7M Buy
3,767,911
+628,780
+20% +$3.87M 4.39% 6
2013
Q2 		$19.3M Buy
+3,139,131
New +$16.2M 3.77% 9

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Broadfin Capital's AVDL Position: Q4 2019 in Review

Broadfin Capital reduced its Avadel Pharmaceuticals (AVDL) stake by 67% in Q4 2019, selling an estimated $11M and leaving 1,029,012 shares worth $7.77M. The position accounts for 1.04% of the portfolio, ranked #28.

Broadfin Capital first reported a position in AVDL in Q2 2013 and has held it in 27 quarters since. The position peaked at $105M in Q2 2015. 42 funds tracked by Wall St. Rank hold AVDL as of Q4 2019.

  • Broadfin Capital held 1,029,012 shares of Avadel Pharmaceuticals worth $7.77M as of Q4 2019.
  • Broadfin Capital sold 2,073,661 Avadel Pharmaceuticals shares in Q4 2019, an estimated $11M.
  • Avadel Pharmaceuticals made up 1.04% of Broadfin Capital's portfolio in Q4 2019, its #28 holding.
  • Broadfin Capital first reported a position in Avadel Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
  • Broadfin Capital's Avadel Pharmaceuticals position peaked at $105M in Q2 2015.
  • 42 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.